Management

Craig H. Misrach, M.B.A., C.P.A. – President and Chief Executive Officer


Craig H. Misrach is the President and Chief Executive Officer of Freedom Meditech and has over 10 years of finance experience with start-up and midsize organizations. Prior to Freedom Meditech, Mr. Misrach was the President and Chief Operating Officer of EyeCh em, a developmental stage diabetes medical device company focused on the commercialization of an eye-related blood glucose measuring and monitoring system. At EyeChem, Mr. Misrach crafted and executed the financing, operating, and marketing strategies of the organization while simultaneously overseeing the contract manufacturing and product development activities of the company. Mr. Misrach was successful in obtaining initial start-up capital and infrastructure support for the organization.

Prior to EyeChem, Mr. Misrach was Controller and Assistant Vice President of Silvergate Capital Corporation, a $500M asset-based diversified finance organization. At Silvergate, Mr. Misrach was the primary liaison for executive management regarding the revenue and expense activities of the organization and gained extensive operational and management experience during a two year period of fast-paced corporate growth from 28 to 79 employees. Silvergate was a client of Mr. Misrach at Deloitte and Touche, where he was the Lead Senior Accountant for a $60M IPO and audited various biotechnology, medical device, and healthcare companies.

Mr. Misrach is a Certified Public Accountant (C.P.A.) in the State of California and has a B.S in Accounting and Finance from Indiana University. Mr. Misrach also has an M.B.A. in General Management and Entrepreneurship & Venture Capital from the Darden Graduate School of Business at the University of Virginia.

Brent D. Cameron Ph.D. – Chief Scientific Officer

Dr. Brent D. Cameron is currently the Director and Associate Professor of Bioengineering at the University of Toledo. His current efforts are focused on developing methods to allow for noninvasive physiological glucose measurement. Over the past 10 years, Dr. Cameron has written several papers and had his research findings published in reputable diabetes magazines for his work using polarized light to monitor glucose levels within the aqueous humor of the eye.

Other investigations of Dr. Cameron include the development of smart spinal disc implants and the development and testing of a device used in photo-biotherapy. Dr. Cameron is also working on a technique which employs the use of surface enhanced Raman spectroscopy (SERS) for cytochrome P450s characterization towards the development of therapeutic drug monitoring.

Dr. Cameron has a B.S. and M.S. in Bioengineering from Texas A&M University. Dr. Cameron obtained his Ph.D. in Biomedical Engineering from Texas A&M University. A detailed listing of Dr. Cameron’s published papers and grants awarded can be provided upon request.

Brian Catanzaro, Ph.D. – VP of Product Development, Lead Optical Engineer

Brian Catanzaro, Ph.D. is an independent consultant in the field of optical engineering. He holds a Ph.D. in Applied Physics from the Electrical and Computer Engineering Department of University of California, San Diego as well as a B.S. degree in Applied Physics from the California Institute of Technology. Dr. Catanzaro has published numerous papers in various fields including hyperspectral instrumentation, biological sensors, biomedical devices, stable structures for space borne instruments, and optical metrology. He has been active in the aerospace, telecommunications, microlithography, semiconductor fabrication, head mounted display, military sensor, biological sensor, and biomedical device industries. His expertise includes product development in areas of advanced optical technology. This includes optical design, optical analysis, prototyping, and testing of optical systems. In addition, he is well versed in mechanical and thermal analyses in support of opto-mechanical system design, analysis, and fabrication.

Dr. Catanzaro has been involved with several biotech instruments and medical devices. Dr. Catanzaro has designed genetic array sequencing, using confocal instruments and optical resonator technologies. He has also designed and developed the optics, opto-mechanics, and opto-electronics for medical devices that address: stroke therapy, non-invasive glucose measurement, drug infusion, ocular measurements for contact lens fitting, and stem cell sorting.

Paul Willams - VP of Research and Development

Mr. Williams comes to Freedom Meditech with more than 15 years of experience in startup environments, leading multi-disciplinary teams in development, manufacturing and launch of Class II and Class III medical diagnostic and therapeutic devices. Over the past ten years, Mr. Williams has led engineering departments in multiple ventures involving diabetes and glucose measurement.

As the VP of Engineering at Oculir, Inc., Mr. Williams led development of the company's first-generation laboratory system to measure glucose non-invasively in the human eye. Prior to Oculir, as Director of Engineering at DexCom, Inc., Mr. Williams led development of the world's first long-term implantable glucose sensor. He guided the project through three generations of prototypes, andimal and human testing, and FDA approval.

Mr. Williams holds and M.S. in Fluid Mechanics and a B.S. in Mechanical Engineering, both from Oklahoma State University.

Mark R. Miehle - VP of Distribution

Mark R. Miehle, as Freedom Meditech’s Vice President of Distribution, brings a results-driven focus and demonstrated success in sales, marketing, operations, business development and strategic planning. Mr. Miehle is an entrepreneurial leader with a track record of positioning companies for growth in the medical device industry, a keen strategist adept at building dynamic organizations and a creative problem solver with deep experience in managing distribution channels and international marketing efforts.

Prior to joining Freedom Meditech, Mr. Miehle was the president of Birmingham, AL based CW Allen Group, where he increased sales by 266% in his first year alone and nearly quadrupled client contracts. Prior to CW Allen, Mark served for 12 years as President and CEO of San Diego-based Vismed, Inc. Mr. Miehle led the company through the transition from an R&D start-up to a profitable organization, brought 4 imaging products to market and developed world-wide sales channels. In 2000, Vismed was acquired by Paradigm Medical Industries, and Mr. Miehle continued as President and CEO of the combined company, where he managed the post-merger integration and grew sales revenue by 33% in its first year.

Mr. Miehle is a graduate of Tulane University in New Orlean, LA, where he earned his B.S. in Organic Chemistry and a minor in Finance. He is a member of the Young Presidents’ Organization and is actively involved in the ophthalmic industry, as a member of the Optical Laboratories Association, the Vision Industry Council of America and the Ophthalmic Photographer’s Society.